FindTrial
Sign In

Real-world Efficacy and Safety of Immune check point inhibitors for Refractory Head and Neck Cancer: A Retrospective Multicenter Study

Real-world Efficacy and Safety of Immune check point inhibitors for Refractory Head and Neck Cancer: A Retrospective Multicenter Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0004258
Enrollment
100
Registered
2019-08-29
Start date
2019-08-01
Completion date
Unknown
Last updated
2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Chung-Ang Univerisity Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ? Patients with larynx, oral cavity, oropharynx, nasal cavity, maxillary sinus, hypopharyngeal carcinoma confirmed histologically as squamous cell carcinoma ? Patients who have undergone palliative chemotherapy for relapse after surgery or initial metastasis ? Patients who have received immune checkpoint inhibitors

Exclusion criteria

Exclusion criteria: ? Nasopharyngeal cancer patients ? Patients who have not been observed after a single dose of immune checkpoint inhibitors (follow-up loss) are difficult to confirm the effects or adverse events

Design outcomes

Primary

MeasureTime frame
Objective response rate—

Secondary

MeasureTime frame
Progression Free Survival;Duration of response;Overall Survival;Incidence of Hyperprogression;Incidence of Immune related adverse events—

Countries

Korea, Republic of

Contacts

Public ContactIn Gyi Hwang

Chung-Ang Univerisity Hospital

hematoonco@naver.com+82-2-6299-1403

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026